We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
A phase II study of withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable molecular remission
Scientific title
A phase II study to determine relapse-free interval after withdrawal of imatinib therapy in adult patients with chronic phase chronic myeloid leukaemia in stable complete molecular remission
Secondary ID [1] 254 0
Australasian Leukaemia and Lymphoma Group (ALLG): ALLG CML8
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic phase chronic myeloid leukaemia in stable molecular remission 1083 0
Condition category
Condition code
Cancer 1163 1163 0 0
Leukaemia - Chronic leukaemia

Study type
Description of intervention(s) / exposure
This is a non-randomised Phase 2 clinical study. Patients who have achieved a stable complete molecular response on imatinib mesylate treatment (i.e. undetectable BCR-ABL mRNA for at least 2 years) will stop imatinib treatment and be monitored closely for molecular evidence of early relapse. Monitoring off treatment will continue until relapse or for a maximum of 2 years. Patients who relapse will resume imatinib treatment and close monitoring will continue to assess the molecular response to re-treatment. Monitoring in the re-treatment phase will continue until complete molecular response is confirmed or for a maximum of 12 months.
Intervention code [1] 965 0
Treatment: Drugs
Comparator / control treatment
No comparator.
Control group

Primary outcome [1] 1568 0
To assess what proportion of CML patients with stable complete molecular response (CMR) on imatinib for at least 2 years remain in complete molecular response (without recurrence of RQ-PCR-detectable BCR-ABL in blood)
Timepoint [1] 1568 0
For 2 years after ceasing imatinib therapy
Secondary outcome [1] 2822 0
1. To assess the proportion of patients who, after ceasing imatinib for up to 2 years, have recurrence of detectable BCR-ABL that is NOT eradicated within 12 months of re-starting imatinib.
Timepoint [1] 2822 0
Secondary outcome [2] 2823 0
2.To assess the proportion of patients who, after ceasing imatinib for up to 2 years, have recurrence of detectable BCR-ABL but maintain a major molecular response, or regain a major molecular response or complete molecular response within 12 months of restarting imatinib.
Timepoint [2] 2823 0
Secondary outcome [3] 2824 0
3.To assess the proportion of patients who develop cytogenetic or haematological relapse in the two years after cessation of imatinib
Timepoint [3] 2824 0
Secondary outcome [4] 2825 0
4.To establish the rate of molecular relapse-free survival after cessation of imatinib treatment (MRFS).
Timepoint [4] 2825 0
Secondary outcome [5] 2826 0
5.To assess quality of life and resolution of any identified imatinib toxicity during the period of drug withdrawal.
Timepoint [5] 2826 0

Key inclusion criteria
1. Diagnosis of chronic myeloid leukaemia associated with BCR-ABL quantifiable by RQ-PCR at the time of commencing imatinib therapy 2. Treatment with imatinib for at least 3 years 3. No other current or planned anti-leukaemia therapies 4. Sustained complete molecular response of leukaemia (assessed by undetectable levels of BCR-ABL by RQ-PCR in blood or marrow, for 2 years or longer, tested on at least 2 occasions per year and confirmed by the central PCR laboratory at IMVS using a technique with sensitivity of at least 4 logs) 5. No signs of extramedullary leukaemia 6. ECOG Performance status 0, 1, or 2 (see Section 6.1.2) 7. Female patients must have a negative pregnancy test within one week before starting imatinib OR have been amenorrhoeic for at least two years. All patients of reproductive potential must agree to birth control for the duration of the study monitoring and re-treatment phases. 8. Life expectancy of more than 12 months in the absence of any intervention 9. Patient has given written, informed consent to participate in the study (which includes consent to obtain samples for the correlative study) and has been given the option to participate in tissue banking.
Minimum age
18 Years
Maximum age
Not stated
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Patient has received another investigational agent within last 2 years.2. Currently receiving imatinib treatment as part of a clinical trial (including Extension Phase of IRIS trial)3. Administration of cytokine therapy (e.g. G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry.4. Atypical BCR-ABL transcript not quantifiable by standard RQ-PCR.5. Another primary malignant disease, except those which do not currently require treatment (adequately treated conditions, such as excised skin cancer or cervical intra-epithelial neoplasia would not be considered exclusion criteria. If in doubt, please refer to the Principal Investigator). 6. Another severe and/or life-threatening medical disease. 7. Active liver disease (e.g., chronic active hepatitis, cirrhosis).8. Known diagnosis of human immunodeficiency virus (HIV) infection. 9. History of non-compliance or inability to grant informed consent.10. Prior allogeneic stem cell transplantation11. Interruption of imatinib therapy for a cumulative period in excess of 14 days in the preceding 3 months.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Not yet recruiting
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1271 0
Commercial sector/Industry
Name [1] 1271 0
Novartis Australia
Address [1] 1271 0
Country [1] 1271 0
Primary sponsor type
Other Collaborative groups
Australasian Leukaemia and Lymphoma Group
Secondary sponsor category [1] 1126 0
Name [1] 1126 0
Address [1] 1126 0
Country [1] 1126 0

Ethics approval
Ethics application status

Brief summary
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 35311 0
Address 35311 0
Country 35311 0
Phone 35311 0
Fax 35311 0
Email 35311 0
Contact person for public queries
Name 10154 0
Dr David Ross
Address 10154 0
Division of Haematology
Institute of Medical and Veterinary Science
PO Box 14
Rundle Mall SA 5000
Country 10154 0
Phone 10154 0
+61 8 82223566
Fax 10154 0
+61 8 82223162
Email 10154 0
Contact person for scientific queries
Name 1082 0
Dr David Ross
Address 1082 0
Division of Haematology
Institute of Medical and Veterinary Science
PO Box 14
Rundle Mall SA 5000
Country 1082 0
Phone 1082 0
+61 8 82223566
Fax 1082 0
+61 8 82223162
Email 1082 0

No information has been provided regarding IPD availability
Summary results
No Results